Sanofi's Consumer Division Cushions Blow From Rx Exclusivity Losses
This article was originally published in The Tan Sheet
Sanofi-Aventis' expanding consumer health division is a shining beacon for growth even as the pharma giant plunges off a prescription drug patent cliff.
You may also be interested in...
Sanofi-Aventis gains a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys.
A joint venture with Minsheng Pharmaceutical Group brings Sanofi-Aventis one step closer to its goal of doubling its consumer health care business in five years and opens a powerful distribution channel in China through which the French firm can market newly acquired supplements
Sanofi-Aventis' $1.9 billion bid for OTC and personal care product firm Chattem offers the French firm a coveted toehold in the sizeable U.S. consumer health care market while also opening potential opportunities in emerging markets